Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overweight and raises the price target from $1.8 to $2.
Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overweight and raises the price target from $1.8 to $2.